Prostate Cancer

Steroid sulfatase inhibition showed early activity as a precision option in castrate-resistant prostate cancer, including the potential to enhance response to enzalutamide.

In men who had radical prostatectomies for intermediate and high-risk disease, a delay of up to 12 months did not result in any worse outcomes compared to immediate surgery within 3 months of diagnosis.

The phase 3 CONDOR study demonstrated excellent diagnostic performance with 18F-DCFPyL–PET/CT in men with biochemically relapsed prostate cancer, even at very low PSA values.

A study found no association between Black race and risk of skeletal-related events and all-cause mortality in men with newly diagnosed, bone metastatic castration-resistant prostate cancer.

The most frequent treatment changes triggered by 18F-DCFPyL PSMA PET/CT were a shift from observation or systemic therapy to surgery or radiation, or adding nodal-directed therapy to radiation or salvage surgery.

Findings create opportunity to develop precision medicine options for this underserved patient population.

At 10 years, the risk of distant metastasis was 0.6%.

Abnormalities in the androgen receptor gene detected in men with advanced prostate cancer were associated with poor responses to available drug treatments and reduced survival.

Samuel J. Peretsman, MD, discusses which patients with prostate cancer can be treated with HIFU, contraindications to the treatment, and what expectations patients need to have postoperatively.

Dr. Badar M. Mian highlights the safety and efficacy of relugolix, describing the drug as an “exciting new option” for patients with recurrent or advanced prostate cancer.

William Lowrance, MD, and Michael S. Cookson, MD, highlight the core components of the new AUA Guideline for Advanced Prostate Cancer.

The American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology have released a joint guideline for advanced prostate cancer to address the growing treatment options and complexity of the paradigm.

A real-world analysis found that nerve sparing robot-assisted radical prostatectomy increased the risk of ipsilateral positive surgical margins.

177Lu-PSMA-617, an investigational radioligand therapy, showed stronger clinical activity than cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.

The FDA has granted a priority review to relugolix for the treatment of patients with advanced prostate cancer

Phase 3 data showed that the addition of the AKT inhibitor ipatasertib to standard therapy boosted radiographic progression-free survival in patients with advanced castration-resistant prostate cancer whose tumors had PTEN loss.

Following radical prostatectomy, circulating tumor cells may indicate an increased risk of recurrence earlier than a PSA rise.

MRI-guided laser focal therapy showed a better safety profile than standard treatments for patients with localized prostate cancer.

The regimen of apalutamide, abiraterone acetate, and prednisone showed viability as an ADT-free alternative in patients with advanced prostate cancer with noncastrate testosterone levels.

Three codes are available for prostate biopsy, but only one is typically used for perineal biopsy, according to Jonathan Rubenstein, MD, and Mark Painter.

In this video, Eric Klein, MD, discusses a study evaluating the 17-gene Oncotype DX Genomic Prostate Score assay in African American and Caucasian American men.

The classifier can be a useful adjunct for clinical decision-making, an investigator says.

This final analysis of the phase 3 PROSPER study supports enzalutamide and androgen deprivation therapy as the standard of care to improve overall survival in prostate cancer patients before the onset of detectable metastasis.

Apalutamide (ERLEADA) combined with androgen deprivation therapy improves overall survival more than androgen deprivation therapy alone in men with non-metastatic castration-resistant prostate cancer at high risk of metastases, according to results from investigators’ final analysis of the phase 3 SPARTAN trial.

The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.